Literature DB >> 20408737

Safety of intravenous immunoglobulin treatment.

James B Caress1, Burton L Kennedy, Kara D Eickman.   

Abstract

IMPORTANCE OF THE FIELD: Intravenous immunoglobulin (IVIg) is a biologic pharmaceutical that is widely used to treat immunodeficiency conditions and a variety of autoimmune conditions. It is under-recognized that IVIg can be associated with severe complications including death. AREAS COVERED IN THIS REVIEW: This review will address common mild side effects and extensively discuss the uncommon but serious complications of IVIg. Mild constitutional reactions include headache, fever and rash and severe complications include anaphylaxis, acute renal failure, stroke and myocardial infarction. IVIg has been used to treat autoimmune illnesses for ~30 years and the literature since then is reviewed with special attention to reports in the last 10 years that detail the serious adverse events. WHAT THE READER WILL GAIN: The reader will understand that mild side effects are common and that these can be ameliorated with pre-treatment medications. They will also become familiar with the risk factors for serious complications so that careful patient and IVIg product selection will result in fewer poor outcomes. TAKE HOME MESSAGE: IVIg is quite safe across age groups although serious adverse reactions occur particularly in elderly individuals with multiple cardiovascular risk factors and those with preexisting renal failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20408737     DOI: 10.1517/14740338.2010.484419

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  17 in total

Review 1.  Intravenous immunoglobulin as clinical immune-modulating therapy.

Authors:  Laurent Gilardin; Jagadeesh Bayry; Srini V Kaveri
Journal:  CMAJ       Date:  2015-02-09       Impact factor: 8.262

2.  Serum immunoglobulin G levels and peritonitis in peritoneal dialysis patients.

Authors:  Cécile Courivaud; Karine Bardonnet; Thomas Crepin; Catherine Bresson-Vautrin; Jean-Michel Rebibou; Didier Ducloux
Journal:  J Nephrol       Date:  2015-03-11       Impact factor: 3.902

3.  Characteristics of late-onset myasthenia gravis.

Authors:  Saša A Zivković; Paula R Clemens; David Lacomis
Journal:  J Neurol       Date:  2012-04-05       Impact factor: 4.849

Review 4.  RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Authors:  Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

Review 5.  Special considerations with the use of intravenous immunoglobulin in older persons.

Authors:  M Jennifer Cheng; Colleen Christmas
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

6.  Payor issues: barriers to optimal management of patients with primary immunodeficiency.

Authors:  Ralph S Shapiro; Marcia Boyle
Journal:  J Clin Immunol       Date:  2012-08-25       Impact factor: 8.317

Review 7.  Therapeutic management of primary immunodeficiency in older patients.

Authors:  Nisha Verma; Anthony Thaventhiran; Benjamin Gathmann; James Thaventhiran; Bodo Grimbacher
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

8.  Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.

Authors:  Joseph W Golden; Marina Zaitseva; Senta Kapnick; Robert W Fisher; Malgorzata G Mikolajczyk; John Ballantyne; Hana Golding; Jay W Hooper
Journal:  Virol J       Date:  2011-09-20       Impact factor: 4.099

9.  Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors:  Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal:  Am Health Drug Benefits       Date:  2019-10

10.  In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations.

Authors:  F Dhainaut; P-O Guillaumat; H Dib; G Perret; A Sauger; C de Coupade; M Beaudet; M Elzaabi; L Mouthon
Journal:  Vox Sang       Date:  2012-09-25       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.